RT Journal Article
SR Electronic
T1 Tracking Immunity: Increased number of COVID-19 boosters increases the longevity of anti-RBD and anti-RBD neutralizing antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.25.24317883
DO 10.1101/2024.11.25.24317883
A1 Hou, Ching-Wen
A1 Williams, Stacy
A1 Boyle, Veronica
A1 Roeder, Alexa
A1 Bobbett, Bradley
A1 Garcia, Izamar
A1 Caruth, Giavanna
A1 Magee, Mitch
A1 Chung, Yunro
A1 Lake, Douglas
A1 LaBaer, Joshua
A1 Murugan, Vel
YR 2024
UL http://medrxiv.org/content/early/2024/11/28/2024.11.25.24317883.abstract
AB Background/Objectives Since the World Health Organization declared COVID-19 a pandemic in March 2020, the virus has caused multiple waves of infection globally. Arizona State University (ASU), the largest four-year university in the United States, offers a uniquely diverse setting for assessing immunity within a large community. This study aimed to evaluate SARS-CoV-2 antibody seroprevalence and the effects of infection and vaccination three years into the pandemic.Methods A serosurvey was conducted at ASU from January 30 to February 3, 2023. Participants completed questionnaires about demographics, respiratory infection history, symptoms, and COVID-19 vaccination status. Blood samples were analyzed for anti-receptor binding domain (RBD) IgG and anti-nucleocapsid (NC) antibodies, offering a comprehensive view of immunity from both natural infection and vaccination.Results The seroprevalence of anti-RBD IgG antibodies was 96.2% (95% CI: 94.8%-97.2%), and 64.9% (95% CI: 61.9%-67.8%) of participants had anti-NC antibodies. Anti-RBD IgG levels correlated strongly with neutralizing antibody levels, and participants who received more vaccine doses showed higher levels of both anti-RBD IgG and neutralizing antibodies. Increasing number of exposures through vaccination and/or infection resulted in higher and long-lasting antibodies.Conclusion The high levels of anti-RBD antibodies observed reflect substantial vaccine uptake within this population. Ongoing vaccination efforts, especially as new variants emerge, are essential to maintaining protective antibody levels. These findings underscore the importance of sustained public health initiatives to support broad-based immunity and protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Arizona State University Knowledge Enterprise, grant number NA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Arizona State University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.